

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6776

Title: ROLE OF ENDOSCOPIC ULTRASOUND IN THE MOLECULAR DIAGNOSIS OF PANCREATIC CANCER

Reviewer code: 00001390

Science editor: Cui, Xue-Mei

Date sent for review: 2013-10-29 22:01

Date reviewed: 2013-11-15 03:47

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This manuscript reviewed the molecular analysis of samples obtained by EUS-FNA in assessing diagnosis or prognosis of pancreatic cancer, especially in locally advanced tumors. Among many promising candidates, they stressed the clinical usefulness of Kras mutation assay that improves diagnosis of pancreatic cancer. In the differentiation between benign pancreatic mass and pancreatic cancer using EUS-FNA samples, wild-type Kras is evocative of benignity whereas mutated Kras is highly evocative of pancreatic adenocarcinoma. Their review will provide useful information in the clinical trial of the molecular analysis of samples obtained by EUS-FNA in assessing diagnosis or prognosis of pancreatic cancer. However, it is better to add the description of Kras mutation assay for autoimmune pancreatitis that should be differentiated from pancreatic cancer. Is mutated-Kras specific for pancreatic cancer? Is mutated-Kras found in benign pancreatic lesions, such as chronic pancreatitis or autoimmune pancreatitis?